Posted by Michael Wonder on 08 Oct 2021
Genentech’s anti-amyloid beta antibody gantenerumab granted FDA breakthrough therapy designation in Alzheimer’s disease
8 October 2021 - Gantenerumab is an investigational antibody in Phase 3 development for early Alzheimer's disease.
Genentech today announced that gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted breakthrough therapy designation by the U.S. FDA for the treatment of people living with Alzheimer’s disease.
